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Medulloblastoma is the most common pediatric
malignant brain tumor. Although current therapies
improve survival, these regimens are highly toxic
and are associated with significant morbidity. Here,
we report that placental growth factor (PlGF) is ex-
pressed in the majority of medulloblastomas, inde-
pendent of their subtype. Moreover, high expression
of PlGF receptor neuropilin 1 (Nrp1) correlates with
poor overall survival in patients. We demonstrate
that PlGF and Nrp1 are required for the growth and
spread of medulloblastoma: PlGF/Nrp1 blockade
results in direct antitumor effects in vivo, resulting
in medulloblastoma regression, decreased metas-
tasis, and increased mouse survival. We reveal that
PlGF is produced in the cerebellar stroma via
tumor-derived Sonic hedgehog (Shh) and show that
PlGF acts through Nrp1—and not vascular endothe-
lial growth factor receptor 1—to promote tumor cell
survival. This critical tumor-stroma interaction—mediated by Shh, PlGF, and Nrp1 across medullo-
blastoma subtypes—supports the development of
therapies targeting PlGF/Nrp1 pathway.INTRODUCTION
Medulloblastoma is the most common malignant pediatric
brain tumor and constitutes 20% of all brain tumors in children
(Louis et al., 2007). The standard of care includes initial
surgery followed by radiation and chemotherapy. Despite high
survival rates with current regimens, patients encounter devas-
tating morbidity, including decline in cognition and intellect
(Fouladi et al., 2005) and secondary malignancies (Goldstein
et al., 1997). Therefore, there is an urgent need for new therapies
that reduce the significant morbidity associated with current
treatments.
Medulloblastomas can be classified into at least four distinct
molecular groups, suggesting the possibility of developing tar-
geted therapies directed against key drivers (Northcott et al.,
2012). For example, therapy targeting Sonic hedgehog (Shh)
signaling, a driver of one genetic subset of medulloblastomas,
showed promising results initially (Rudin et al., 2009). However,Cell 152, 1065–1076, February 28, 2013 ª2013 Elsevier Inc. 1065
tumors rapidly developed resistance mutations (Yauch et al.,
2009), thus emphasizing the importance of alternative targeted
treatment strategies. Targeting tumor-stroma interactions could
provide an alternative targeting strategy, given the critical role of
the tumor microenvironment in cancer progression and greater
genetic stability of the stromal compartment (Carmeliet and
Jain, 2011; Fukumura et al., 2010; Goel et al., 2011).
Placental growth factor (PlGF) is a member of the vascular
endothelial growth factor (VEGF) family and is involved in bone
marrow-derived cell activation, endothelial stimulation, patho-
logic angiogenesis, and wound healing (Carmeliet et al., 2001;
Fischer et al., 2008; Dewerchin and Carmeliet, 2012). PlGF is
overexpressed in breast and gastric carcinomas but downregu-
lated in colon and lung carcinomas (Fischer et al., 2007; Xu and
Jain, 2007). Whereas in some models, PlGF promotes tumor
growth (Schmidt et al., 2011), in other models, PlGF inhibits
tumor growth (Xu et al., 2006). PlGF is mitogenic and proangio-
genic (Ziche et al., 1997), and blockade of PlGF has resulted in
antiangiogenic and antitumor effects in some models (Fischer
et al., 2007; Van de Veire et al., 2010), but not in others (Bais
et al., 2010). VEGF receptor 1 (VEGFR1), the only known tyrosine
kinase receptor for PlGF, was shown to be required for certain
tumors that respond to anti-PlGF therapy (Yao et al., 2011).
However, direct inhibition of VEGFR1 activity did not explain
anti-PlGF effects in other models (Casanovas et al., 2005; Daw-
son et al., 2009), suggesting an alternative signaling mechanism
for PlGF independent of VEGFR1.
Because PlGF is dispensable during development, we pro-
posed anti-PlGF as a therapeutic approach for pediatric tumors
(Jain and Xu, 2007). Here, we demonstrate that PlGF is neces-
sary for medulloblastoma growth, irrespective of genetic back-
ground. We found that PlGF is produced by the cerebellar
stroma in response to Shh ligand secreted by tumor cells. We
also found that in medulloblastoma, PlGF signaling via Nrp1
and not VEGFR1 directly conveys prosurvival signals and that
Nrp1 expression correlated with poor overall survival. Together
with the reported minimal side effects of anti-PlGF blockade
(Fischer et al., 2007; Lassen et al., 2012), these findings identify
PlGF and Nrp1 as potential targets for therapy of pediatric
medulloblastoma.
RESULTS
PlGF Is Expressed in Medulloblastomas, Regardless of
Their Genetic Background
By immunohistochemistry (IHC), we found that PlGF is ex-
pressed in a variety of brain tumors of children and adults,
including medulloblastoma, ependymoma, atypical teratoid,
rhabdoid tumor, and glioblastoma (Figures 1A and 1C). We
compared expression of angiogenic and vascular remodeling
factors in pediatric medulloblastomas (n = 5) against normal
pediatric cerebella (n = 2; 3 and 5 years of age) and normal adult
cerebella (n = 4; all >60 years of age). We found a marked over-
expression of PlGF (14-fold) and Nrp1 (11-fold) in tumor tissues.
VEGF receptors were either slightly upregulated (VEGFR2/KDR;
2-fold) or modestly downregulated (VEGFR1/FLT1; 2.6-fold)
(Figure 1B; Table S1 available online). The patterns of gene
expression in medulloblastoma and immature brain were quite1066 Cell 152, 1065–1076, February 28, 2013 ª2013 Elsevier Inc.similar, suggesting that factors active during cerebellar develop-
ment may also be activated in pediatric brain tumors.
We analyzed 32 clinical samples of different medulloblas-
toma subtypes by IHC. Of these tumors, 90% (29 in 32)
diffusely expressed PlGF (Figures 1C and 1D) across all World
Health Organization (WHO) subtypes (Louis et al., 2007) and all
main molecular subtypes of medulloblastoma, with the lowest
expression in the Wnt group (Figure 1D). Although both PlGF
receptors were expressed, Nrp1 expression was more striking
than VEGFR1 (Figures 1C and S1A). Analysis of publicly avail-
able copy number data (Tumorscape, Broad Institute) showed
13% of medulloblastomas with gains of the chromosomal
region containing PlGF (Figure S1B), suggesting one direct
genetic mechanism of PlGF upregulation. Taken together, our
data show that PlGF is present in the majority of human
medulloblastomas and is not associated with any particular
subtype.
PlGF Blockade Leads to Medulloblastoma Regression
Mice with D283-MED and D341-MED human medulloblastoma
xenografts exhibited clinical symptoms (CS) in a period of
3 to 4 weeks from implantation and showed a similar profile
to clinical samples (Figures 1C and S1C). Using the same
classification methods (Taylor et al., 2012), D341-MED were
classified as Group 3 and D283-MED as Group 4 medullo-
blastoma, respectively (Figure 1D). These tumors grew rapidly
and spread along the spinal cord via cerebrospinal fluid
(Figure 2A), closely resembling the clinical behavior of human
medulloblastoma.
We treated established tumors with TB403, a dual block-
ing antibody for human and murine PlGF from Roche (Nielsen
and Sengeløv, 2012). TB403 (aPlGF [R]) treatment led to
inhibition of primary tumor growth and spinal metastasis
(Figures 2A, 2B, and S1D). Anti-PlGF-treated mice survived
significantly longer both in the D283-MED (p < 0.0001, 60%
no CS) and D341-MED (p < 0.0001, 70% no CS) models
(Figure 2C).
We also tested the effects of another dual anti-human/murine
anti-PlGF antibody (Ab), C9.V2 from Genentech (Bais et al.,
2010). C9.V2 (aPlGF [G])-treated D283-MED-bearing mice
showed a significant survival increase (Figure 2C) and a delay
in tumor growth, although not tumor regression (Figure S1E).
We next evaluated the effect of anti-PlGF blockade in Smo/
Smo transgenicmice (Hatton et al., 2008). Immunohistochemical
analysis of medulloblastomas from Smo/Smo mice—represen-
tative of the Shh subgroup of tumors—showed expression of
PlGF and Nrp1 (Figure 1C). When Smo/Smo mice reached
6–8 weeks of age, we treated with the murine specific anti-
PlGF antibody 5D11D4 (Fischer et al., 2007) orC9.V2 for 3weeks.
Anti-PlGF-treated mice had significantly smaller tumors and less
body weight loss (body weight 29.4 g versus 23.1 g, p = 0.0044)
and did not show a hunched posture seen in control-treated
mice (Figures 2D and 2E).
Furthermore, PlGF levels in Smo/Smo mice with established
medulloblastoma were dramatically increased compared to
wild-type mice (Figure S1F). Together, these data indicate that
PlGF contributes to the progression of medulloblastoma and
can be targeted by a number of different anti-PlGF antibodies.
Figure 1. Expression of PlGF and Its Receptors in Brain Tumors
(A) Expression of PlGF in malignant brain tumors. PlGF was abundantly expressed in clinical samples of ependymoma (90%), glioblastoma (100%), and atypical
teratoid and rhabdoid tumor (100%), but only in 25% of retinoblastoma (example of a negative tumor shown).
(B) Expression profile of angiogenic molecules in medulloblastoma is similar to immature cerebellum. Expression of PlGF, Nrp1, and Nrp2 is increased in
medulloblastoma when compared to adult cerebella, whereas expression of VEGFR1 (Flt1) is mildly decreased.
(C) Strong expression of PlGF and Nrp1 is present in clinical samples of medulloblastoma, immortalized humanmedulloblastoma cell lines D283-MED and D341-
MED, as well as in the transgenic spontaneous Smo/Smo medulloblastoma. VEGFR1 expression is much lower compared to Nrp1.
(D) PlGF is expressed in 90% of medulloblastomas across WHO subtypes by IHC. Based on molecular classification, Wnt medulloblastomas, the least
aggressive subtype, show the lowest percent of PlGF positivity, whereas Group 3 and 4 show expression of PlGF in 100%of clinical specimens.Medulloblastoma
models (D283, D341, and Smo/Smo) used in our studies molecularly correspond to different subtypes. The asterisk indicates that molecular classification was
applied based on criteria using the IHC panel proposed by the medulloblastoma consensus group (Taylor et al., 2012), array comparative genomic hybridization
for copy number changes, and deep gene sequencing for mutations. The double asterisk indicates that tumors with discordant immunohistochemical and/or
molecular features were named unclassifiable.
See also Figure S1 and Table S1.Medulloblastoma Recruits Host-Derived Cerebellar
Stromal Cells that Secrete PlGF and Sustain Tumor
Growth
We found that circulating murine (m)PlGF levels were highest
in younger mice and that the medulloblastoma growth was
enhanced in younger mice (Figures S1G and S1H). Further,
growth of untreated D283-MED tumors was accompanied by
a significant increase in tumor-derived human (h)PlGF in the
cerebellum and in the blood (Figure 3A). The levels of stromal
murine PlGF (mPlGF) also increased with time and, by 5 weeks,
contributed to about 80% of the total blood PlGF concentration
(mPlGF = 15 pg/ml; human PlGF [hPlGF] = 3 pg/ml).Implantation of D283-MED with hPlGF silenced (Figures S1I
and S1J) resulted in significant delays in tumor growth and spinal
cord spread and increased survival (Figures 3B and 3D). These
tumors also induced substantially lower levels of host stromal
mPlGF secretion (Figure 3A). Thus, initial production of hPlGF
by the tumor cells appeared critical for the initial growth of
the tumors and stimulation of stromal mPlGF production. Re-
expression of PlGF2 in a PlGF small hairpin RNA (shRNA)-30
UTR construct in D283-MED cells (Figure S1I) rescued rapid
tumor growth and short survival phenotype (Figures 3B and 3D).
To determine the importance of stromal PlGF, we blocked
mPlGF with 5D11D4 either starting at day one after tumorCell 152, 1065–1076, February 28, 2013 ª2013 Elsevier Inc. 1067
Figure 2. Inhibition of PlGF Leads toRegression ofMedulloblastoma
(A) Whole-body imaging of D283-MED tumors transfected with GLuc. We
initiated treatment 3 weeks after implantation, when tumors produced clinical
symptoms and were apparent by whole-body imaging (arrowheads). Addi-
tionally, small spinal cord dropmetastases were observed at 3 weeks (arrows).
At 6 weeks, IgG-treated control tumors have progressed both in the cere-
bellum (red arrowheads) and spine (red arrows), whereas aPlGF [R] (TB403)-
treated tumors have regressed in both the cerebellum (yellow arrowheads) and
spine (yellow arrows).
(B) Blood GLuc measurement is a marker of total tumor burden. aPlGF [R]
(TB403) therapy is initiated 3 weeks (D283-MED) or 4 weeks (D341-MED) after
implantation of medulloblastoma tumors. Treated tumors showed a significant
decrease in total tumor burden (*p < 0.001 at endpoint, n = 10/group, mean ±
SEM). Error bars represent SEM.
(C) Survival was significantly increased in both orthotopic models with anti-
PlGF inhibition (**p < 0.0001, n = 10/group). The D283 model was treated with
both the Roche antibody TB403 (aPlGF [R]) and the Genentech antibody
C9.V2 (aPlGF [G]). The D341 model was treated with TB-403. All aPlGF [R]-
treated mice that survived at the end of study showed no clinical symptoms.
(D and E) Murine-specific anti-PlGF Ab 5D11D4 (amPlGF) shows similar effect
in Smo/Smo spontaneous model of medulloblastoma. (D) At the endpoint of
the study, amPlGF-treated animals showed no clinical symptoms, such as
hunched posture and had preserved body weight (**p = 0.0044, n = 8/group)
and (E) significant decreased tumor size (measured in cross-section, **p =
0.047 and p = 0.01, amPlGF and aPlGF as compared to corresponding
controls, respectively; n = 8/group, two separate experiments, animals
randomized by age and sex). Mice were treated with the murine-specific
1068 Cell 152, 1065–1076, February 28, 2013 ª2013 Elsevier Inc.implantation (prevention) or starting at day 21 when tumors pro-
duced CS (intervention). Mice treated from day one had signifi-
cantly lower tumor burden, no spinal spread, and increased
average overall survival (p < 0.0001) (Figure 3C), similar to mice
with tumors that had genetically silenced PlGF (62.5% no CS
in both PlGF-inhibited groups, Figure 3D). Mice treated from
day 21 showed significant reduction in the size of primary tumors
and in the average number of spinal metastases per mouse
(2.0 versus 5.0, p < 0.001) (Figure 3E) and prolonged survival
(p < 0.0001, 60% no CS) (Figures 3C and 3D). There was a small
additional effect of TB403 (which blocks both hPlGF and mPlGF)
compared to 5D11D4 (which only blocks mPlGF) (Figure S1K).
We then implanted Smo/Smo medulloblastoma tumors in the
cerebellum of syngeneic plgf/ mice. We found a significantly
lower tumor take rate, delayed growth, and increased survival
in the plgf/ mice compared to the wild-type controls (2/10
versus 11/11; Figures 4A and S2A). Overall, our results indicate
that medulloblastoma tumor cells secrete PlGF but that a sub-
stantial proportion of PlGF is derived from the stroma andmedul-
loblastoma growth requires stromal PlGF.
Tumor-Secreted Shh Ligands Stimulate Paracrine
Stromal Production of PlGF
We investigated stromal production of PlGF and examined the
role of Shh, a key driver of tumorigenesis in medulloblastoma.
Tumor-derived Shh ligands were shown to sustain tumorigen-
esis by signaling activation in the stromal compartment (Walter
et al., 2010). D283-MED and D341-MED medulloblastoma
models secreted Shh ligands (Figure S2B), despite absence of
genetic changes in Shh pathway. For stroma, we isolated cere-
bellar glial and external granule layer cells, neither of which
produced a significant amount of basal Shh or PlGF (Figures
4B, 4C, and S2C). Stimulation with Shh induced a dose-depen-
dent secretion of PlGF by granule cells but had no detectable
effect on glial cells (Figure 4B). Stimulation of Wnt pathway,
which is also involved in normal cerebellum development (Pei
et al., 2012), by Wnt-3a or Wnt-7a proteins did not induce PlGF
secretion (Figure S2D). Medulloblastoma cells were unrespon-
sive to Shh stimuli, perhaps due to high basal levels of endoge-
nous PlGF in vitro (Figure S2E).
In cocultures of isolated mouse granule cells and D341-MED
cells, the secreted levels of Shh increased in a time-dependent
manner and correlated with increased secretion of mPlGF
(Figure 4C). Treatment with the Shh inhibitor cyclopamine led
to a significant decrease in circulating mPlGF levels in mice
bearing D283-MED (Figure 4D). In addition, we found that
medulloblastoma-bearing mice treated with anti-mPlGF therapy
had increased circulating hPlGF (Figure 4E), whereas tumors
decreased in size (Figure 3C). These tumors also showed upre-
gulated expression of Shh and its effector Gli1 (Figure 4F).
Collectively, these data suggest that medulloblastoma co-opts
the stroma to produce PlGF through paracrine Shh signaling,
possibly through activation of Gli1. Furthermore, the tumor
responds to a dramatic drop in stromal PlGF levels by secretingantibody 5D11D4 (amPlGF) or the Genentech anti-PlGF antibody (aPlGF [G]).
Error bars represent SEM.
See also Figure S1.
Figure 3. Role of Stromal PlGF in Growth of
Medulloblastoma
(A) Growth of orthotopically implanted D283-MED
humanmedulloblastoma leads to increased hPlGF
as well as mPlGF in cerebellum and peripheral
blood. In later phases of growth (day 35 post-
implantation), murine PlGF represents 80% of
circulating PlGF.WhenPlGF is genetically silenced
in tumor cells (shRNA), there is a corresponding
significant decrease in murine PlGF production
(*p<0.01, n =10/group). Error bars represent SEM.
(B) Mice implanted with two different shRNA
PlGF-knockdown tumors (PlGF shRNA1 3UTR
and PlGF shRNA2) show significantly delayed
tumor growth in shPlGF tumors (*p < 0.0001 at
endpoint, n = at least 8/group). 3UTR indicates
shRNA targeting the 30 UTR of PlGF. Re-expres-
sion of PlGF in the shRNA1 3UTR cells (PlGF
shRNA1 3UTR + PlGF) resulted in rescued tumor
growth. Error bars represent SEM.
(C) Inhibition of stromal PlGF in D283-MED or
D341-MED tumors by anti-mouse PlGF (amPlGF)
5D11D4 led to delayed growth and stabilization of
the tumor (*p<0.0001at endpoint, n=10/group). In
the D283-MED model, treatment with amPlGF
5D11D4 from day 1 after implantation (D283
amPlGFP, prevention trial) led to a growth delay
similar to shPlGF inhibition (*p < 0.0001 at
endpoint, n = 10/group). Error bars represent SEM.
(D) Both shRNA knockdown of PlGF and inhibition
of stromal PlGF resulted in increased mouse
survival in both D283-MED and D341-MED
models (**p < 0.0001, n = 10/group). Re-expres-
sion of PlGF in shRNA tumor cells compromised
the survival benefit with anti-mPlGF antibody. All
of the surviving anti-PlGF-treated mice showed no
evidence of clinical symptoms.
(E) Spinal cord spread of medulloblastoma is a
sign of highly aggressive disease. Controls had
large metastatic nodules in the spinal cord (arrow),
whereas anti-PlGF-treated mice had only a thin
layer of malignant cells but no mass formation
(arrowhead). Histology showed that inhibition of
stromal PlGF therapy resulted in a significant
decrease of metastasis (*p = 0.002, n = 10/group).
Data are presented as mean ± SEM.Shh, upregulating Gli1, and increasing tumor cell production of
PlGF as a compensatory mechanism (Figures 3A and 4E). We
downregulated Shh with shRNA in tumor cells (D283-shSHH
tumors) and showed significant growth delay and significant
increase in survival (p < 0.001, Figures 4G and 4H).
Blockade of PlGF Has Modest Effects on Angiogenesis
and No Effect on Tumor-Associated Macrophages in
Medulloblastoma
PlGF regulates the angiogenic switch, and anti-PlGF therapy can
inhibit angiogenesis in some tumor models (Fischer et al., 2007;
Rolny et al., 2011). We analyzed the number and function of
vessels in anti-PlGF Ab-treated or shPIGF medulloblastomas.
We found a significant but modest decrease in tumor microvas-
cular density (30% decrease, p < 0.0001, Figures 5A and 5B)
but no change in tumor vessel diameter, vascular permeability,
or hypoxic fraction (Figure S3A; data not shown).Inhibition of PlGF may also affect tumors by reducing tumor-
associated macrophage (TAM) infiltration (Fischer et al., 2007)
or by inducing TAM polarization toward an antitumor phenotype
(Rolny et al., 2011). We analyzed changes in TAMs in medullo-
blastoma after PlGF blockade. Medulloblastomas had a very
small number of TAMs at baseline, and anti-PlGF therapy did
not significantly change the TAM recruitment or polarization (Fig-
ure S3B). Thus, the effects of anti-PlGF therapy on angiogenesis
and TAMs are unlikely to mediate the dramatic tumor reduction
measured by optical frequency domain imaging (OFDI) (Figures
5C and 5D).
PlGF Directly Activates Prosurvival Pathways in
Medulloblastoma
We next sought to determine whether PlGF has direct effects
on medulloblastoma cells. We stimulated D283-MED and D341-
MED cells with recombinant hPlGF (rhPlGF) and Smo/SmoCell 152, 1065–1076, February 28, 2013 ª2013 Elsevier Inc. 1069
Figure 4. Role of Shh in Stromal PlGF
Secretion
(A) Smo/Smo allografts implanted in cerebellums
of wild-type and plgf/ mice. T2-weighted
magnetic resonance (MR) images showed a large
tumor in the cerebellum of wild-type mice 5 weeks
after implantation (red circle and arrow). This
tumor burden resulted in obstruction and enlarged
ventricles (red arrowhead). Tumors implanted in
plgf/ mice did not grow with normal cerebellum
readily apparent (white arrow) and plgf/ ex-
hibited normal ventricular volume (white arrow-
head).
(B) Granule cells secreted higher baseline levels of
PlGF compared to glial cells. When recombinant
Shh was added to the medium, granule cells
significantly increased PlGF production (*p =
0.0159), whereas glial cells did not respond to
Shh stimulation with increased PlGF production
(p = 0.80). Data are from three independent
experiments, presented as mean ± SEM.
(C) When tumor cells (D341-MED) were cultured
with granule cells, there was an increase of Shh
(*p = 0.0043 day 5, **p = 0.0387 day 6) as well as
increased murine/stromal PlGF (*p = 0.0096 day 5;
**p = 0.041 day 6), further confirming the role of
Shh in stromal PlGF production. Data are from
three independent experiments, presented as
mean ± SEM.
(D) Mice bearing D283-MED tumors were treated
with cyclopamine, a broad spectrum Shh inhibitor
and showed a significant decrease of circulating
stromal/murine PlGF (p < 0.0001, n = 10/group,
mean ± SEM).
(E) Inhibition of stromal PlGF by 5D11D4 led to
increased production of human PlGF after 1 week
(*p < 0.01) and 3 weeks of anti-PlGF therapy (**p <
0.0001) in mice bearing D283-MED tumors. There
was also decreased production of human soluble
Flt1 in both groups (#, ##p < 0.01 for both
comparisons). After initial decrease after 1 week
(^ p = 0.05), circulating hVEGFA rebounds after
3 week treatment (n = 8/group, mean ± SEM).
(F) Inhibition of stromal PlGF was accompanied by
increased secretion of Shh and increased Gli1
expression in D283-MED medulloblastoma as
evaluated by IHC.
(G and H) Genetic inhibition of Shh in D283-MED
(shSHH) led to delayed tumor growth (G) and
increased survival (H, *p < 0.001 at endpoint, n = 8/
group).
See also Figure S2.medulloblastoma cells isolated from transgenic mice with
recombinant mPlGF and evaluated the activation of canonical
survival pathways. Stimulation with PlGF induced marked phos-
phorylation of the prosurvival/progrowth factor ERK1/2 in all
medulloblastoma lines as well as activation of PI3K/Akt in the
Smo/Smo cells (Figures 6A, S4A, and S4B). We used the MEK
inhibitor U0126 to block ERK activation and to test whether
maintenance of mitogen-activated protein kinase (MAPK)
signaling is essential for medulloblastoma viability. We found
that treatment with U0126 induced a rapid decrease in medullo-
blastoma cell viability (Figure S4C).1070 Cell 152, 1065–1076, February 28, 2013 ª2013 Elsevier Inc.We compared the levels of ERK1/2 activation and apoptosis in
control versus treated tumor tissues. Blockade of stromal PlGF
by 5D11D4 induced a decrease in pERK1/2 and increase in
apoptosis of tumor cells in both the xenograft and transgenic
models but no difference in cell proliferation (Figure S5). Overall,
these data suggest that stromal PlGF actively sustains the sur-
vival of tumor cells through activation of the MAPK cascade.
Survival Signaling Is Mediated via Nrp1, but Not VEGFR1
To determine the transduction of PlGF survival signaling, we
investigated the role of Nrp1 and VEGFR1. We established a
Figure 5. Inhibition of PlGF Has Moderate Antiangiogenic Effect on Medulloblastoma
(A and B) (A) Two-photonmicroscopy 3weeks after implantation showsmedulloblastoma (blue) surrounded by small vessels (green, DiD-labeled red blood cells).
After treatment with amPlGF Ab (5D11D4), there was some regression of small vessels detected by two-photon microscopy (white arrows) or (B) IHC (*, **p <
0.001 for both comparisons, n = 8/group). Scale bar, 100 mm. Error bars represent SEM.
(C) OFDI shows tumor vasculature (color-coded map), and transverse scans (white dotted line, red arrow) show tumor structure that can be directly correlated
with histology. Tumor (T, yellow dotted line) and normal (N) tissue directed matched between OFDI and histology.
(D) OFDI directly shows tumor regression with aPlGF treatment. The red dotted line represents the tumor area observedwith OFDI, and the yellow line is the tumor
diameter that was quantified during treatment (right).
See also Figure S3.stable D283-MED shNRP1-GFP-tagged cell line and tested the
response of high versus low Nrp1-expressing cell populations
to rhPlGF. Cells with relatively low level of Nrp1 knockdown
(selected as 5% GFP-dimmest cells) showed activation of
ERK1/2, whereas cells with high level of Nrp1 knockdown
(lowest Nrp1 expression, selected as top 5% GFP-brightest
cells) failed to activate ERK in the presence of PlGF (Figure 6B).
D283-MED shNRP1 tumors exhibited a significant growth delay
in mice (Figure S6A) and did not exhibit spinal cord metastasis
(Figures 6C and 6D), which significantly extended survival (p <
0.0001, 43% no CS) (Figure 6E). D283-MED shNRP1 tumors
had preserved proliferation activity measured by Ki-67, implying
that genetic inhibition of Nrp1 does not affect medulloblastomacell proliferation (Figure S6D). Interestingly, genetic silencing of
Nrp2 did not affect growth of tumor cells in vitro or in vivo
(data not shown).
We treated human medulloblastoma cell lines and murine
Smo/Smo cells with species-specific Nrp1-blocking antibodies
and analyzed PlGF-mediated activation of MAPK and Akt
signaling. We detected increased pERK1/2 and pAkt after
PlGF stimulation. Blockade of Nrp1 prevented the activation of
ERK1/2 and Akt by PlGF to a similar extent compared to anti-
PlGF antibody (Figure 6A).
A recent report suggested that response to anti-PlGF therapy
is restricted to a subset of VEGFR1-expressing tumors (Yao
et al., 2011). VEGFRs are classically necessary partners ofCell 152, 1065–1076, February 28, 2013 ª2013 Elsevier Inc. 1071
Figure 6. PlGF Signaling in Medulloblastoma Is Dependent on Nrp1
(A) Serum starvation decreased phosphorylation of Erk1/2 in D283-MED and D341-MED cells and decreased phosphorylation of Akt in Smo/Smo cells. PlGF
stimulation increased phosphorylation of Erk1/2 in D283-MED, D341-MED, and Smo/Smo medulloblastoma cells and increased phosphorylation of Akt in Smo/
Smomedulloblastoma cells. Inhibition of either PlGF or Nrp1 with species-specific antibodies resulted in decreased phosphorylation of Erk1/2 or Erk1/2 and Akt,
respectively.
(B) When Nrp1 was expressed, adding PlGF increased phosphorylation of Erk1/2 in D283 medulloblastoma cells, but not when Nrp1 was genetically silenced.
(C) Nrp1 knockdown D283-MED (shNRP1) and D283-MED with an overexpressed mutant form of Nrp1 that does not have a cytoplasmic domain (Nrp1-DSEA)
showed substantial tumor growth delay and absence of spinal spread as measured by whole-body imaging.
(D) GLuc blood measurements also showed a significant tumor growth delay in shNRP1 tumors (*p < 0.01, n = 10/group, mean ± SEM).
(E) D283-MED shNRP1 tumor-bearing mice had a significant increase in survival (*p < 0.0001, n = 10/group). Surviving animals at the end of study showed no
clinical symptoms.
(F) D283-MED Nrp1-DSEA tumor-bearing mice had an increased survival with no clinical symptoms (*p < 0.01, n = 4/group).
(G) Mice with VEGFR1 knockdown D283-MED cells (shVEGFR1) were implanted in the cerebellum and showed no change in tumor growth.
(legend continued on next page)
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Figure 7. Growth of Medulloblastoma Depends on Shh-Mediated Secretion of PlGF and Nrp1 Signaling
(A and B) Inhibition of Nrp1 by a specific anti-Nrp1 antibody resulted in inhibition of tumor growth and spinal spread as well as increased survival (*p < 0.01, n = 4/
group).
(C) Analysis of a clinical cohort of 42 children with medulloblastoma that had been treated according to the HIT 91’ and HIT 2000 protocols reveals that high Nrp1
expression is significantly correlated with poor survival.
(D) Initial medulloblastoma growth is dependent on autocrine PlGF signaling. With growth of the tumor, secreted Shh, perhaps through Gli1, stimulates stromal
granule cells to produce PlGF, and this paracrine signaling further facilitates rapid medulloblastoma growth. PlGF signaling via Nrp1 leads to increased phos-
phorylation of Erk1/2 and survival of tumor cells. This leads to uncontrolled growth of the primary tumor and spread to the spinal cord.Nrp1 for effective signal transduction (Bielenberg et al., 2006).
Thus, we next examined the relative role of VEGFR1 in PlGF
signaling in medulloblastoma. When we coimmunoprecipitated
VEGFR1 and Nrp1 in unstimulated and PlGF-stimulated D283-
MED and Smo/Smo cells, VEGFR1 and Nrp1 were pulled
down together. However, we found very small differences in
the amount of complex between control and stimulated cells
and minor differences in tyrosine phosphorylation of VEGFR1
before and after PlGF stimulation (Figure S6B; data not shown).
Moreover, when we genetically inhibited VEGFR1 in D283-MED
cells (D283-MED shVEGFR1), we found no effect on pERK1/2
following PlGF stimulation (Figure S6C). Furthermore, when we
implanted stable D283-MED shVEGFR1 cells in vivo, we found
that the tumors with VEGFR1 downregulation exhibited no differ-
ence in growth (Figures 6G and S6E). Finally, when we crossbred
Smo/Smo transgenic mice (Hatton et al., 2008) with VEGFR1/
Flt1-tyrosine kinase knockout (flt1TK/) mice (Hiratsuka et al.,
1998), we found that double homozygote (Smo/Smo/flt1TK/)
mice developed tumors similar to Smo/Smo transgenic mice,
further showing that VEGFR1 activity is not necessary for devel-
opment of medulloblastoma (Figure 6H).
The Intracellular Domain of Nrp1 Is Essential for Effect
of PlGF
Nrp1 is a receptor with short cytoplasmic tail and is widely re-
garded as a nonsignaling receptor. To determine whether Nrp1(H) Cross-breeding of Smo/Smo mouse with Flt1 tyrosine kinase-deficient mous
signaling domain in medulloblastoma. (Left) T2-weighted MR image of the Smo/
(arrow) that (right) was confirmed as a medulloblastoma similar to one arising in
See also Figures S4, S5, and S6.is involved in transduction of downstream PlGF signaling, we
overexpressed a mutant form of Nrp1 in D283-MED cells
(Nrp1-DSEA) that retains its functional binding sites for PlGF
but lacks the three intracellular C-terminal amino acids (SEA-
COOH) that bind PDZ-adaptor signaling proteins and is unable
to transduce signaling. Mice bearing medulloblastomas with
overexpressed Nrp1-DSEA showed significant tumor growth
delay and increased survival (p < 0.01, 100% no CS) (Figures
6C and 6F). These results demonstrate that PlGF activation of
intracellular Nrp1-mediated signaling is a requirement for cell
growth and survival in medulloblastoma.
In the therapeutic setting, mice treated with anti-Nrp1 anti-
body (Pan et al., 2007) showed significant tumor growth delay
and improved survival (p < 0.01, 100% no CS) (Figures 7A and
7B). Moreover, we found that high expression of Nrp1 in tumors
significantly correlates with decreased overall survival in an inde-
pendent cohort of medulloblastoma patients (p = 0.0058) (Fig-
ure 7C). Collectively, these results support evaluation of the
available PlGF and Nrp1 antibodies in medulloblastoma patients
(Lassen et al., 2012; Martinsson-Niskanen et al., 2011; Weekes
et al., 2010).
DISCUSSION
The role of PlGF in cancer remains unclear, perhaps due to
context-dependent effects of this growth factor in tumore (flt1TK/) was performed to investigate the role of VEGFR1 tyrosine kinase
Smo/flt1TK/ mouse shows a nodular lesion in the left cerebellar hemisphere
the Smo/Smo/ flt1TK+/+ (Flt1-tk wild-type) mouse (Figure 1B).
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progression. We show here that (1) PlGF is expressed in the
majority of human pediatric medulloblastomas, regardless of
their molecular/genetic subtype, and is required for the growth
and spread of three subtypes of medulloblastoma models in
mice; (2) the majority of PlGF protein is secreted by cerebellar
stromal cells in vivo; (3) stromal PlGF production is stimulated
via paracrine Shh secretion by the cancer cells; and (4) the
PlGF/Nrp1/MAPK signaling axis is critical for survival of medullo-
blastoma in vitro and in vivo (Figure 7D). These findings provide
insights into the role of Shh, PlGF, and Nrp1 in medulloblastoma
and offer a different approach to targeted therapy.
There may be several mechanisms of PlGF upregulation in
medulloblastoma, including copy number gain or mutations of
PlGF or its regulators. In addition, medulloblastoma cells also
secrete Shh, which stimulates production of stromal PlGF.
Because we observed a strong tumor dependence on stromal-
derived PlGF, blockade of PlGF presents targeted therapy that
bypasses the tumor cell and disrupts a tumor-stroma interaction
that is vital for disease progression. Our study provides insight
into a role for Shh inmedulloblastoma that seems to be unrelated
to the tumor’s genetic origin and provides a potential for use of
Shh pathway inhibitors. If stimulation of Shh pathway in stromal
cells is crucial for production of survival factor PlGF, inhibition of
Shh signaling in stromal cellsmight prove to be as important as in
the tumor cells without facing a challenge of acquired genetic
resistance (Metcalfe and de Sauvage, 2011). Combined Shh
and PlGF inhibition might therefore offer the maximum benefit
in disrupting tumor-stroma interactions.
The exact role of PlGF in tumor growth and the potential
benefit of its inhibition has been a matter of intense debate
(Bais et al., 2010; Coenegrachts et al., 2010; Fischer et al.,
2007, 2008; Rolny et al., 2011; Schmidt et al., 2011; Van de Veire
et al., 2010; Xu et al., 2006; Yao et al., 2011). What has emerged
from our work is that the utility of PlGF inhibition in the clinic will
be tumor context dependent. We propose that tumor type,
stage, microenvironment, and maybe even age of the patient
will be major contributors to the outcome of therapy. While, in
some tumors, PlGF may be important as an angiogenic factor,
in other tumors—such as medulloblastoma—it might represent
a vital growth factor for tumor survival. Although PlGF-binding
receptors have been extensively studied (Fischer et al., 2008),
the exact downstream signaling and role in cancer cell survival
is not well understood. Yao et al. (2011) have shown that the
effect of anti-PlGF inhibition depends on the presence of func-
tional VEGFR1 in tumor cells. However, another report showed
that genetic ablation of VEGFR1 tyrosine kinase domain in the
host had no effect on tumor growth (Bais et al., 2010). Our study
shows the critical importance of Nrp1 in medulloblastoma and
reveals PlGF/Nrp1 axis as a necessary survival mechanism.
The cytoplasmic protein docking (SEA) domain of Nrp1 is neces-
sary for PlGF prosurvival signal transduction. Taken together,
these data indicate that either PlGF or Nrp1 inhibition can pro-
vide therapeutic benefit.
Intriguingly, despite the initial tumor stabilization and regres-
sion, none of the treatments led to complete eradication of
medulloblastomas. After initial regression, tumors reached a
plateau and persisted without clinical symptoms. When investi-
gated by IHC, these remaining tumors showed reduced Nrp11074 Cell 152, 1065–1076, February 28, 2013 ª2013 Elsevier Inc.expression (Figure S5A). The mechanisms of resistance after
anti-PlGF therapy in medulloblastoma remain to be deci-
phered. Although we did not observe tumor recurrence in our
models, it is conceivable that cells that do not depend on
PlGF/Nrp1 axis for survival could lead tomedulloblastoma recur-
rence. Therefore, anti-PlGF or anti-Nrp1 therapy in medulloblas-
tomawould likely be used in concert with conventional regimens.
Recent clinical trials of humanized anti-PlGF antibody TB403
showed that anti-PlGF therapy was well tolerated with minimal
side effects (Lassen et al., 2012; Martinsson-Niskanen et al.,
2011).
Both TB403 and 5D11D4 therapy led to regression of medul-
loblastoma, which was dependent on Nrp1 signaling. C9.V2
was also active but induced a growth delay rather than tumor
regression. This antibody has been reported to have the best
effects in VEGFR1-dependent tumors (Yao et al., 2011), presum-
ably by blocking PlGF-VEGFR1 interaction, but may be less
potent in blocking PlGF-Nrp1 interaction (Bais et al., 2010).
However, 5D11D4 was shown to potently block binding of
PlGF to both Nrp1 and VEGFR1 (Fischer et al., 2007). This raises
an important issue for development of therapeutic antibodies. In
medulloblastoma PlGF signals via Nrp1 and therapy with an anti-
body blocking predominantly the interaction with VEGFR1 that
might be efficacious in VEGFR1-overexpressing tumors (Yao
et al., 2011) would likely be less effective than an antibody that
potently blocks PlGF interaction with Nrp1.
In summary, we show that both tumor and stromal-derived
PlGF signal through Nrp1 to directly sustain growth and spread
of medulloblastoma, and inhibition of this pathway leads to
regression and improved mouse survival. In conjunction with
the low adverse effects, the PlGF/Nrp1 axis represents a prom-
ising target for therapy of medulloblastoma.
EXPERIMENTAL PROCEDURES
Clinical Samples, Histology, and Molecular Classification
Deidentified samples of medulloblastoma, ependymoma, glioblastoma,
AT&RT, retinoblastoma, and normal cerebella were obtained from the Depart-
ment of Pathology, Massachusetts General Hospital, after institutional review
board approval (protocol 2008-P-000079/3) and 42 clinically annotated
samples treated according to the German HIT ‘91 protocol (Rutkowski et al.,
2007) and the subsequent HIT 2000 protocol (ClinicalTrials.gov Identifier:
NCT00303810) at the University Children’s Hospital, Mu¨nster, Germany,
between the years of 1998 and 2010 were collected following institutional
approval.
Cell Lines and Animal Models
Human medulloblastoma cell lines included D283-MED (American Type
Culture Collection [ATCC] Number: HTB-185) and D341-MED (ATCC Number:
HTB-187) (Friedman et al., 1985, 1988). Smo/Smo medulloblastoma mice
(Hatton et al., 2008) were obtained from the Jackson Laboratory. flt1TK/
mice (Hiratsuka et al., 1998) were generously provided by Dr. Shibuya, Tokyo
University, Japan. Plgf/ mice were obtained from Dr. Anne Croy, Queen’s
University, Kingston, Canada.
Anti-PlGF and Anti-Nrp1 Antibodies
5D11D4, a specific anti-murine PIGF antibody, and TB403, a dual anti-human/
murine PlGF antibody previously used in translational studies and phase I clin-
ical trials (Lassen et al., 2012; Martinsson-Niskanen et al., 2011; Fischer et al.,
2007) were provided by Hoffmann-La Roche, Inc. Both anti-PlGF Abs were
administered by intraperitoneally (i.p.), three times/week, 25 mg/kg. C9.V2
dual anti-human/murine anti-PlGF antibody (Bais et al., 2010; Yao et al., 2011)
was kindly provided by Genentech and applied i.p. twice a week, 30 mg/kg.
Specific human anti-Nrp1 antibody (Pan et al., 2007) was provided by Genen-
tech and applied i.p. twice a week, 10 mg/kg.
Cyclopamine Treatment
Severe combined immunodeficiency (SCID) mice bearing D283-MED were
treated with a single dose of cyclopamine (Sigma-Aldrich, MO), 25 mg/kg,
subcutaneously. Samples were collected 48 hr after injection.
Tumor Growth and Response to Therapy
Tumor growth, progression, and response to therapy were followed by (1) clin-
ical evaluation of posterior fossa symptoms and body weight, (2) whole-body
bioluminescence and blood GLuc levels, (3) small animal MRI, (4) and OFDI.
Tumors were evaluated by IHC after harvesting.
Isolation of Granular Cells and Tumor-Stroma Coculture
Cerebellar granule cells were purified as previously described (Hatten, 1985)
with slight modifications. Cocultures of granule cells and D341-MEDwere per-
formed at a 1/1 or 1/2 ratio.
ELISA
ELISA studies were performed on plasma using MS6000 Human Growth
Factor I Kit (PlGF, VEGF, sFlt1, and bFGF; Meso-Scale Discovery, Gaithers-
burg, MD) measured on SI2400 (Meso-Scale Discovery). ELISA measure-
ments formPlGFwere performed using aQuantikineMP200 kit (R&DSystems,
Minneapolis, MN) measured on a Benchmark Plusmicroplate spectrophotom-
eter (Bio-Rad Laboratories, Hercules, CA). The levels of hShh in conditioned
medium from granule cells/D341-MED cocultures were measured using the
hShh ELISA kit (ab100639; Abcam, Cambridge, MA).
Cell Viability
Medulloblastoma cells were cultured with indicated concentrations of MEK
inhibitor U0126 or control vehicle for 48 hr. Cell viability was assessed by quan-
tifying metabolic active cells through measurements of cellular contents of
ATP using the CellTiter-Glo luminescence assay (Promega, WI).
Immunoblotting and Coimmunoprecipitation
The following antibodies and reagents were used: PlGF, hVEGFR1, and
mVEGFR1 (Abcam); Nrp1, VEGFR2, Shh, phospho-ERK1/2(Thr202/Tyr204),
and ERK1/2; phospho-Akt(Ser473), Akt, b-Actin, c-Caspase3, and anti-rabbit
immunoglobulin G (IgG)-HRP (Cell Signaling, MA); tubulin and anti-mouse IgG-
HRP (Sigma-Aldrich); and U0126 (Calbiochem, MA).
PCR Arrays, qRT-PCR, and shRNA Studies
Gene expression was performed using a commercially available human
angiogenesis PCR array (PAHS-024; SABiosciences, CA) according to the
manufacturer’s guidelines.Mission human-shPLGF, human shNRP1, and non-
targeting shRNA control lentiviral transduction particles were purchased from
Sigma. Retroviral shVEGFR1 and shSHH was obtained from OriGene. Cells
were infected according to manufacturer’s protocol.
Statistical Analyses
All data are expressed as mean ± SEM. Survival curves are plotted with the
Kaplan-Meier method. For statistical analysis, JMP Statistical analysis soft-
ware was used (SAS Institute, NC). Two-tailed t tests were used between
data comparing only two groups. Least-squares means contrasts were used
to assess significance of multiple data points, such as tumor growth curves.
For survival data, a log rank test was employed. We considered a p value
less than 0.05 to be statistically significant. For further details, please refer
to Extended Experimental Procedures.
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